Microbiome Therapies Market: By Species; Therapy Type; Microbes; Diagnosis; Application; By End-Use & Geography - Forecast 2018 to 2023

  • ID: 4532402
  • Report
  • 163 pages
  • IndustryARC
1 of 3
Microbiome is a collective genome of microorganisms that reside inside and outside of the body, ranging from pathogenic to beneficial. Microbiota hosts on a biotic as well as an abiotic body.

The Microbiome Therapies market is broadly classified on the basis of various parameters. The market has been divided based on Human, Animal and Plant species. By the type of therapies for each species classified as Microbiome Addition, Removal & Nourishment and many others, also by types of microbes- Eubacteria, Bacteria, Archae, Fungi and Virus. On the basis of diagnosis- analyzers, reagents and other solutions. The market has been split by the application areas such as Pharmaceuticals, Food & Beverage and others also by End-Users in Testing Centres, Research Labs, Farms, Medical and Food outlets and as well as based on geographical analysis.

The market is led by U.S. region, due to the growing number of startups and huge investments by ventures. The growing concern for health in Middle East and APAC regions will significantly drive the market for Microbiome Therapies in these markets. APAC region will have the fastest growing market during the forecast period as improving research facilities, concern towards various life forms and growing programs driving research in this region will drive the market.
Key market players analysed are- uBiome, Evolve BioSystems, Pivot Bio, Inocucor and many others. The advancement in medical and food technologies and continuous investments by big industry tycoons and government, and penetration of start-ups in this market, indicates better prospective in Microbiome Therapies market.
Note: Product cover images may vary from those shown
2 of 3
1. Microbiome Therapies Market Overview

2. Executive Summary

3. Microbiome Therapies – Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End user profiling
3.5. Top 5 Financials Analysis

4. Microbiome Therapies – Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Industry
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition

5. Microbiome Therapies – Market Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis

6. Microbiome Therapies – By Species
6.1. Human
6.2. Animal
6.3. Plant

7. Microbiome Therapies – By Therapy Type
7.1. Microbiome Addition
7.1.1. Microbiome Restorative Therapy (MBRT)
7.1.2. Fecal Microbiota Transplant (FMT)
7.1.3. Probiotics
7.2. Microbiome Removal
7.2.1. Contrabiotics
7.2.2. Phages
7.3. Microbiome Nourishment
7.3.1. Prebiotics
7.4. Targeting Host-Microbiome Interaction
7.4.1. Bacteria Metabolites
7.4.2. Interaction Path
7.5. Others

8. Microbiome Therapies – By Microbes
8.1. Eubacteria
8.2. Bacteria
8.3. Archaea
8.4. Fungi
8.5. Virus
8.6. Protozoa
8.7. Others

9. Microbiome Therapies – By Diagnosis
9.1. Analyzers
9.2. Reagents
9.3. Others

10. Microbiome Therapies – By Application
10.1. Pharmaceuticals
10.2. Food & Beverage
10.3. Healthcare
10.4. Agriculture
10.5. Veterinary
10.6. Others

11. Microbiome Therapies – By End-Use
11.1. Testing Centres
11.2. Research Labs
11.3. Horticulture
11.4. Medical and Food Outlets

12. Microbiome Therapies - By Geography
12.1. Introduction
12.2. Americas
12.2.1. US
12.2.2. Canada
12.2.3. Mexico
12.2.4. Brazil
12.2.5. Argentina
12.2.6. Others
12.3. Europe
12.3.1. Germany
12.3.2. U.K.
12.3.3. France
12.3.4. Spain
12.3.5. Italy
12.3.6. Others
12.4. APAC
12.4.1. Japan
12.4.2. China
12.4.3. India
12.4.4. South Korea
12.4.5. Australia
12.4.6. Others
12.5. ROW
12.5.1. Middle East
12.5.2. Africa

13. Market Entropy
13.1. New Product Launches
13.2. M&As, Collaborations, JVs and Partnerships

14. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
14.1. uBiome
14.2. Evolve BioSystems
14.3. Indigo Agriculture
14.4. Pivot Bio
14.5. Inocucor
14.6. Epibiome
14.7. CosmosID
14.8. Human Longevity, Inc
14.9. Cambrooke Therapeutics
14.10. AnimalBiome

15. Appendix
15.1. Abbreviations
15.2. Sources
15.3. Research Methodology
15.4. Bibliography
15.5. Compilation of Expert Insights
15.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll